Mario Barro is Associate Vice President and Head of FluNXT Advanced Research at Sanofi Pasteur, the largest manufacturer of human vaccines. He is based in Cambridge, Massachusetts. In his present role, he is part of a team focused on the development of Next Generation Influenza Vaccines (NGF) with improved efficacy and broadly protective (BPIV).
Mario Barro earned his PhD in Microbiology at the University of Chile. He completed postdoctoral trainings in bioinformatics at Mount Sinai Scholl of Medicine and virology and innate immunity at the NIAID, NIH. His experience includes acting as PI and Director of Research for a nonprofit start up while leading a novel adjuvant program to improve vaccines for biodefense and emerging infectious diseases. Later, as a Project Officer and Scientist for the Influenza Division in HHS/ASPR/BARDA he provided technical and project direction to multiyear advance development vaccine programs against pandemic and seasonal influenza. He lead collaborative/networks/partnerships for influenza vaccine manufacture and development with CDC, FDA, NIH and NIBSC and implemented strategic roadmap for partnership, network, funding and execution of multi-years government programs. Mario has expertise providing market research and technology evaluations for advance development programs, qualification of services to government and commercial clients, and negotiated contracts between the industry and the US Government. His based scientific training includes Physics, Bioinformatics and Biological Sciences plus more than 25 years leading discovery, preclinical and advance development programs in academic, government and private settings. Participated as member of technical innovation and development evaluation panels for NASA and BARDA programs, NIH study sections, FDA regulatory science panels and WHO committees. He has obtained external funding from federal (NIH, R01) and international organizations (WHO).